A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- Sponsors Biogen
- 28 Jan 2008 Status change from in progress to completed.
- 10 Jan 2007 Status change
- 23 Aug 2005 New trial record.